Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and dosing of 17-N-allylamino-17-demethoxygeldanamycin (tanespimycin) in pediatric patients with relapsed or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Solid Tumor
• Undifferentiated Leukemia

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED